Drug Deliver Business News has carried an article about Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant, the first marketed product to provide maintenance treatment for opioid addiction continuously for six months following a single administration procedure.
The article quotes Titan CEO, Sunil Bhonsle, explaining the benefits of Probuphine, which was cleared by the FDA last year. Mr. Bhonsle notes that in a patient’s fight against addiction, compliance represents a crucial part of recovery. A patient is at risk of relapsing every time he or she misses a dose of their treatment.
The article can be viewed here.